VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO WCGIC 2020 | PANGEA: personalized antibodies for gastroesophageal adenocarcinoma

Daniel Catenacci • 6 Jul 2020
ESMO WCGIC 2020
Gastroesophageal Cancer Gastrointestinal Cancer

Daniel Catenacci, MD, of the University of Chicago, Chicago, IL, discusses the phase IIa PANGEA study (NCT02213289), a precision medicine trial in gastroesophageal adenocarcinoma, evaluating biomarkers for antibody therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Daniel Catenacci

3:40
Updates from the MAHOGANY study in gastric cancer
Daniel Catenacci • 6 Jul 2020
4:06
Bemarituzumab in solid tumors
Daniel Catenacci • 6 Jul 2020
5:59
Perioperative genotype-dosed gFOLFIRINOX with margin-negative resection in gastroesophageal cancer
Daniel Catenacci • 6 Jul 2020

Related Videos

3:15
Health-related quality of life in young CRC survivors
Afsaneh Barzi • 18 Jan 2021
1:31
Disparities in access to screening and variation of targets in different groups
Afsaneh Barzi • 18 Jan 2021
2:39
Onvansertib for second-line treatment of KRAS-mutated mCRC
Heinz-Josef Lenz • 17 Jan 2021
3:08
TAGS: trifluridine/tipiracil in metastatic gastric adenocarcinoma
Michele Ghidini • 17 Jan 2021
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals